|
|
MolecularWare, a subsidiary of CalbaTech, Adds to Senior Management Team with EVP of Business Development
CAMBRIDGE, Mass., August 7, 2003 -
MolecularWare, Inc., a biotech software company, announced today that it has hired industry veteran Justin Lancaster Ph.D as executive vice president of business development. Lancaster is the first new hire by MolecularWare since the firm was acquired by California-based CalbaTech, Inc. (OTC BB: CLBE) in June.
He joins MolecularWare from Molecular Mining Corp., a life sciences software company in the data analysis space, where he had been vice president for business development. Previously Lancaster served as director of marketing at Warner Research LLP, as CEO and founder of Geosoftware Inc., and as founder and executive director of the Environmental Science and Policy Institute.
MolecularWare CEO Richard P. Kivel said Lancaster joined the company as part of its senior management team and brings key market and product knowledge that will help take the company to the next level.
Lancaster said: "MolecularWare has strong business prospects following the acquisition and an opportunity to be a leader in the life sciences software sector. It's a very valuable and promising space, and MolecularWare's DigitalGENOMEŽ product has both a strong user base and room to grow." He added, "I'm very excited to be here."
Lancaster holds an M.S. and a Ph.D in Chemistry from the University of California at San Diego. He has completed postdoctoral research at the CA Space Institute and at Harvard University. A licensed attorney in four states, he also holds a J.D. from Vermont Law School and is a registered patent attorney.
MolecularWare (www.molecularware.com), founded in 1998, provides scientists with software to rapidly store, annotate, and search information derived from high-throughput biology research.
CalbaTech (www.CalbaTech.com) is focused on acquiring and developing early stage companies that are developing next generation products and technologies for life sciences in the U.S. and the U.K.
Note: Certain statements in this news release may contain "forward looking" information within the meaning of rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, may include forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will be accurate and actual results and future events could differ materially from those anticipated in such statements.
DigitalGENOME is a registered trademark of MolecularWare, Inc. All other company names and products are registered trademarks of their respective companies.
|
